Periprocedural antithrombotic therapy during various types of percutaneous cardiovascular interventions

Eur Heart J Cardiovasc Pharmacother. 2016 Apr;2(2):131-40. doi: 10.1093/ehjcvp/pvv053. Epub 2015 Dec 11.

Abstract

Percutaneous catheter-based interventions became a critically important part of treatment in modern cardiology, improving quality of life as well as saving many life. Due to the introduction of foreign materials to the circulation (either temporarily or permanently) and due to a certain damage to the endothelium or endocardium, the risk of thrombotic complications is substantial and thus some degree of antithrombotic therapy is needed during all these procedures. The intensity (dosage, combination, and duration) of periprocedureal antithrombotic treatment largely varies based on the type of procedure, clinical setting, and comorbidities. This manuscript summarizes the current therapeutic approach to prevent clotting (and bleeding) during a large spectrum of interventions: acute and elective coronary interventions, acute stroke interventions and elective carotid stenting, electrophysiology procedures, interventions for structural heart disease, and peripheral arterial interventions.

Keywords: Ablation; Anticoagulants; Antiplatelet drugs; Antithrombotic therapy; Device implantation; Percutaneous interventions; Stents; Thrombolytics.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Coronary Thrombosis / etiology
  • Coronary Thrombosis / prevention & control*
  • Fibrinolytic Agents / therapeutic use*
  • Humans
  • Myocardial Infarction / prevention & control
  • Percutaneous Coronary Intervention / adverse effects
  • Percutaneous Coronary Intervention / methods*
  • Postoperative Complications / prevention & control*

Substances

  • Fibrinolytic Agents